Compare MCI & TECX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | MCI | TECX |
|---|---|---|
| Founded | 1971 | 2019 |
| Country | United States | United States |
| Employees | N/A | 51 |
| Industry | Trusts Except Educational Religious and Charitable | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 423.8M | 393.0M |
| IPO Year | N/A | N/A |
| Metric | MCI | TECX |
|---|---|---|
| Price | $20.10 | $23.11 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $80.40 |
| AVG Volume (30 Days) | 20.9K | ★ 543.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 8.46% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.82 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $11.00 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $18.00 | $13.70 |
| 52 Week High | $23.79 | $27.21 |
| Indicator | MCI | TECX |
|---|---|---|
| Relative Strength Index (RSI) | 42.42 | 56.60 |
| Support Level | $19.31 | $16.88 |
| Resistance Level | $21.23 | $25.39 |
| Average True Range (ATR) | 0.35 | 2.10 |
| MACD | -0.10 | 0.10 |
| Stochastic Oscillator | 9.26 | 80.46 |
Barings Corporate Investors is a closed-end management investment company. Its investment objective is to maintain a portfolio of securities providing a current yield and an opportunity for capital gains. The Trust's principal investments are privately placed, below-investment grade, long-term debt obligations, including bank loans and mezzanine debt instruments. The Trust typically purchases these investments, which are not publicly tradable, directly from their issuers in private placement transactions, and the investments are typically made to small or middle market companies.
Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. Company focus on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.